| Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration … AJM Van den Eertwegh, J Versluis, HP Van den Berg, SJAM Santegoets, ... The Lancet Oncology 13 (5), 509-517, 2012 | 396 | 2012 |
| Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation J Versluis, SD Pas, HJ Agteresch, RA de Man, J Maaskant, MEI Schipper, ... Blood, The Journal of the American Society of Hematology 122 (6), 1079-1086, 2013 | 155 | 2013 |
| Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years JJ Cornelissen, J Versluis, JR Passweg, WLJ Van Putten, MG Manz, ... Leukemia 29 (5), 1041-1050, 2015 | 154 | 2015 |
| Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from … A Bazarbachi, G Bug, F Baron, E Brissot, F Ciceri, I Abou Dalle, H Döhner, ... haematologica 105 (6), 1507, 2020 | 117 | 2020 |
| Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients A Spyridonidis, M Labopin, BN Savani, R Niittyvuopio, D Blaise, ... Bone marrow transplantation 55 (6), 1114-1125, 2020 | 108 | 2020 |
| Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis J Versluis, CLE Hazenberg, JR Passweg, WLJ van Putten, J Maertens, ... The Lancet Haematology 2 (10), e427-e436, 2015 | 103* | 2015 |
| Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1 J Versluis, M Labopin, A Ruggeri, G Socie, D Wu, L Volin, D Blaise, ... Blood advances 1 (7), 477-485, 2017 | 92 | 2017 |
| Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission J Versluis, M Labopin, D Niederwieser, G Socie, RF Schlenk, N Milpied, ... Leukemia 29 (1), 51-57, 2015 | 83 | 2015 |
| Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio J Versluis, R Devillier, WLJ Van Putten, MG Manz, MC Vekemans, ... Leukemia 31 (1), 26-33, 2017 | 68* | 2017 |
| Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow … E Brissot, M Labopin, F Baron, A Bazarbachi, G Bug, F Ciceri, J Esteve, ... Bone marrow transplantation 56 (3), 532-535, 2021 | 54 | 2021 |
| Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT A Nagler, F Baron, M Labopin, E Polge, J Esteve, A Bazarbachi, E Brissot, ... Bone marrow transplantation 56 (1), 218-224, 2021 | 40 | 2021 |
| Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood … R Shouval, JA Fein, M Labopin, C Cho, A Bazarbachi, F Baron, G Bug, ... The Lancet Haematology 8 (3), e205-e215, 2021 | 29 | 2021 |
| Graft-versus-leukemia effect of allogeneic stem-cell transplantation and minimal residual disease in patients with acute myeloid leukemia in first complete remission J Versluis, B Kalin, W Zeijlemaker, J Passweg, C Graux, MG Manz, ... JCO precision oncology 1, 1-13, 2017 | 29 | 2017 |
| Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia C Craddock, J Versluis, M Labopin, G Socie, A Huynh, E Deconinck, ... Journal of internal medicine 283 (4), 371-379, 2018 | 25 | 2018 |
| Circulating endothelial cell enumeration demonstrates prolonged endothelial damage in recipients of myeloablative allogeneic stem cell transplantation N Beije, J Versluis, J Kraan, JW Gratama, S Sleijfer, JJ Cornelissen Haematologica 100 (6), e246, 2015 | 16 | 2015 |
| Risks and benefits in a personalized application of allogeneic transplantation in patients with AML in first CR J Versluis, JJ Cornelissen Seminars in Hematology 56 (2), 164-170, 2019 | 15 | 2019 |
| Optimizing donor choice and GVHD prophylaxis in allogeneic hematopoietic cell transplantation SG Holtan, J Versluis, DJ Weisdorf, JJ Cornelissen Journal of Clinical Oncology 39 (5), 373-385, 2021 | 14 | 2021 |
| Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission R Shouval, M Labopin, D Bomze, GM Baerlocher, S Capria, D Blaise, ... Bone marrow transplantation 55 (12), 2244-2253, 2020 | 12 | 2020 |
| Transplant for TP53-mutated MDS and AML: because we can or because we should? J Versluis, RC Lindsley Hematology 2022 (1), 522-527, 2022 | 11 | 2022 |
| Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the Blood and Marrow … J Versluis, W Saber, HK Tsai, CJ Gibson, LW Dillon, A Mishra, J McGuirk, ... Journal of Clinical Oncology 41 (28), 4497-4510, 2023 | 10 | 2023 |
Myriam LabopinGeverifieerd e-mailadres voor ebmt.org
